Swedencare AB · OMXSTO:SECARE
Swedencare AB — Q3 2021 Earnings Presentation
17 slides from Swedencare AB's earnings presentation, November 2021
Slide 1: Interim Report July – September 2021 Presentation
INTERIM REPORT July – September 2021 Presentation CEO Håkan Lagerberg CFO Jenny Graflind
Slide 2: Q3 2021 Highlights
Q3 2021 Highlights New concepts and new colleagues – a quarter constructing the future Record sales and profit Org. growth impacted by delayed Asian orders – less impact going forward Vetio included from July 1st, visit in Vetio North Supply, Production and Project activities Acquisition of FAV
Slide 3: Key highlights
Key highlights • Many bigger business opportunities discussed and agreed • Fantastic quarter from many group companies, best quarter for 2021 (UK, Nordic, Spain, Pet MD Brands, Stratford) • Solved Brexit challenges, UK-EU • Online growth and investments with excellent ROI • Vetio sales hampered by h
Slide 4: Key highlights
Key highlights • Closed several Pharma projects starting 2022 for Vetio North • Launch of Topicals/dermatology products in Pet Retail channel in USA • Move of Pet MD’s warehouse – larger, more effective with other group companies • Animal Pharm (shift to inhouse Derma production) to Amazon and Chewy
Slide 5: Key Performance Indicators Q3 2021
Key Performance Indicators Q3 2021
Slide 6: Key Performance Indicators YTD 2021
Key Performance Indicators YTD 2021
Slide 7: Financials – Proforma Swedencare TTM Oct 2020 – September 21
Financials – Proforma Swedencare TTM Oct 2020 – September 2021 Proforma - inc. acquisitions last Swedencare 12 months Vetio Eliminations Consolidated Sales 616 86 271 -37 936 GM 362 37 137 536 GM% 58,8% 43% 51% 57% EBITDA 158 6 66 229 EBITDA% 26% 6% 24% 24%
Slide 8: Sales per region Q3
Sales per region Q3 REST OF THE WORLD 1% ASIA zo ‘8% Q3 2021 NORTH AMERICA 75% - REST OF THE WORLD 0, 2 Yo SWEDEN ASIA 2 % 10% 40m REST OF EUROPE Q3 2020 13% NORTH AMERICA 58% ~ 28 SWEDENCARE
Slide 9: Sales per product category Q3
Sales per product category Q3
Slide 10: Sales per product category YTD
Sales per product category YTD
Slide 11: Sales per brand Q3
Sales per brand Q3 OTHER for PETS Professional Veterinary Fermalas PRIVATE/CO LABEL PlaqueOff ANIMAL pharmaceuticals nutravet* rimarscence =p Geman GEA sem STOMAX® GLUCOSAMIN VetWELL Pet MD #8 SWEDENCARE
Slide 12: Rolling 4 Quarters
Rolling 4 Quarters 57 623] --|160 000 600 000 140 000 500 000 120 000 300 000 80 000 200 000 -| 60 000 100 000 40 000 0 -| 20 000 0) Qi @2 Q3 24 Qt G2 Q38 4 Qt Q2 Q38 Q4 At Q2 QB 2018 2019 2020 2021 ME Net revenue MEESITDA _—sMNN EBITDA - adiusted for acauisition costs eds 4 SWEDENCARE
Slide 13: Acquisition of FAV Oct 1st 2021
Acquisition of FAV Oct 1st 2021 • A direct to consumer logistics company for the pet sector • Drop-shipment for Amazon, Chewy, Target, Tractor Supply and more • Swift listing process for new products on above platforms • Access to Amazon Canada and Mexico • Will enable us to make bundle offerings of
Slide 14: Priorities 2021/2022
Priorities 2021/2022 Integration of acquired companies Increased Marketing Brand and Product development Distribution of full product range M&A opportunities Board and management will review the financial target under H2 2021
Slide 15: Q&A
Q&A 1. Introduce equity research has listed that one of the biggest risks for Swedencare is that the patent for PlaqueOff formula runs out in 2021 in the most markets. How do you see this risk playing out and what are you doing to minimize the impact of the patent running out? 2. Vetio contributed w
Slide 16: Q&A
Q&A 4. Is it possible to quantify the sales you had during the quarter that has been pure cross-selling between your different acquired companies? 5. Your D&A increased to 7.3m in the quarter mainly due to Vetio. Is it possible to say anything about what you expect in terms of Capex & D&A going forw
Slide 17: See you soon!
Live Chat starts in 5 min – See you soon!